Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for INNOVENT BIO?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Net income was negative in FY2016, FY2017, FY2018, FY2019, FY2020, FY2021, FY2022, FY2023, FY2024.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 4.27 | 4.56 | 6.21 | 9.42 | 13.0 |
| YoY | 11.1% | 6.7% | 36.2% | 51.8% | 38.4% |
| Net Income (CNY B) | -2.73 | -2.18 | -1.03 | -0.09 | 0.81 |
| Operating Cash Flow (CNY B) | -2.02 | -1.92 | 0.15 | 1.29 | 10.0 |
| ROE | -28.6% | -20.7% | -8.8% | -0.7% | 5.0% |
| Gross Margin | 88.2% | 79.6% | 81.7% | 84.0% | 86.5% |
| Net Margin | -63.9% | -47.8% | -16.6% | -1.0% | 6.2% |
| Debt-to-Assets | 36.4% | 39.0% | 39.3% | 39.3% | 48.2% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | — | 0.02 | 0.01 | 1.05 | 3.84 | 4.27 | 4.56 | 6.21 | 9.42 | 13.0 |
| YoY | — | — | -48.9% | 10953.3% | 266.9% | 11.1% | 6.7% | 36.2% | 51.8% | 38.4% |
| Net Income (CNY B) | -0.50 | -0.56 | -5.77 | -1.72 | -1.00 | -2.73 | -2.18 | -1.03 | -0.09 | 0.81 |
| Operating Cash Flow (CNY B) | -0.36 | -0.49 | -1.01 | -1.66 | -0.31 | -2.02 | -1.92 | 0.15 | 1.29 | 10.0 |
| ROE | — | — | -137.6% | — | -11.4% | -28.6% | -20.7% | -8.8% | -0.7% | 5.0% |
| Gross Margin | — | 100.0% | 100.0% | 88.1% | 89.9% | 88.2% | 79.6% | 81.7% | 84.0% | 86.5% |
| Net Margin | — | -3033.3% | -60900.0% | -164.2% | -26.0% | -63.9% | -47.8% | -16.6% | -1.0% | 6.2% |
| Debt-to-Assets | 134.0% | 166.0% | 31.4% | — | 25.8% | 36.4% | 39.0% | 39.3% | 39.3% | 48.2% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
-
Watch
Inventory DaysFinancial Quality
270.6 days, prior FY 198.7 days(+36%)
FY2025 (ended 2025-12-31) · What is this?
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
No dividends paid over the trailing 12 months.
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.